bristol-myers squibb - Search News

News

Bristol Myers Squibb Cuts Full-Year Adjusted View

Seeking Alpha · 8h

Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade)

Investors weren't impressed with Bristol-Myers Squibb Company's (BMY) Q2 2025 results, with the stock down by 5.8% after earnings. Read the latest stock analysis here.

Yahoo Finance · 13h

Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE?

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article

The Wall Street Journal on MSN · 20h

Bristol Myers Squibb Cuts Full-Year Adjusted View, but Raises Revenue Expectations

Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a charge related to its BioNTech partnership.

Fierce Pharma1d

Bristol Myers touts commercial execution, reckons with recent clinical setbacks

Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...

1d

Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors

Shares of Bristol Myers Squibb Co. BMY slid 5.81% to $43.31 Thursday, on what proved to be an all-around dismal trading ...

1don MSN

Bristol-Myers delivers double beat and raises full-year sales forecast

Bristol-Myers Squibb (BMY) shares rise after beating Q2 forecasts, raising 2025 revenue outlook, and showcasing growth in key ...

1d

Arm Holdings slips on guidance, AbbVie Q2 beat, Bristol-Myers outlook

Market Catalysts host Julie Hyman tracks today's top moving stocks and biggest market stories in this Market Minute. Arm ...

BioPharma Dive3d

Bain leads $300M investment in startup built on Bristol Myers immune drugs

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results